[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100226959":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":26,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Nonoperative","ACTIVE_COMPARATOR","Pneumococcal vaccine (Pneumovax-23) will be administered within 72 hours of injury. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.",[13],"Biological: Pneumovax-23",{"label":15,"type":10,"description":16,"interventionNames":17},"Angioembolization","Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after embolization. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Splenectomy","Pneumococcal vaccine (Pneumovax-23) will be administered 14 days after splenectomy. Baseline antibody levels will be drawn at the time of vaccine administration, with response levels being drawn 4 weeks later.",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":26},"BIOLOGICAL","Pneumovax-23",null,[15,9,19],[29],{"name":30,"affiliation":5,"role":31},"David Shatz, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"David V Shatz, MD","CONTACT","916-734-5535","dvshatz@ucdavis.edu",{"name":39,"role":35,"phone":40,"phoneExt":26,"email":41},"Anthony Calabro, PhD","916-734-4365","arcalabro@ucdavis.edu",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University of California, Davis Medical Center","RECRUITING","Sacramento","California","95817","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-121.4944,38.58157,{"lat":55,"lon":54},[58],{"name":34,"role":35,"phone":26,"phoneExt":26,"email":37},{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100226959","phase-2-immunologic-response-to-pneumococcal-polysaccharide-vaccine-in-splenic-injury-patients-100226959",false,"NCT02232191","Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients","Inclusion Criteria:\n\n* Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.\n\nExclusion Criteria:\n\n* Ages less than 18 and greater than 65\n* Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.","ALL","18 Years","65 Years",{"count":71,"type":72},75,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","Persons without a spleen are susceptible to potentially lethal infections from certain bacteria, with pneumococcus being the most prevalent. Vaccines are provided to help protect against these infections, though they do not so with certainty. Trauma patients who sustain an injury to their spleen currently have three treatment options available for the treating surgeon - nonoperative management, embolization, or removal of the spleen. The purpose of this study is to investigate the antibody response to pneumococcal vaccine in patients undergoing these modes of therapy.",[78],"Asplenia","2025-12-03",{"date":81,"type":82},"2025-12-05","ACTUAL",{"date":84,"type":26},"2014-12",{"date":86,"type":72},"2026-07",{"name":5,"class":6},1]